The effect of postmenopausal hormone therapy with or without folic acid supplementation on serum homocysteine level

Climacteric

Volumn 8, Issue 3, 2005, Pages 279-286

  Toprak, A ^a,b   Erenus, M ^a   Ilhan, A H ^a   Haklar, G ^a   Fak, A S ^a   Oktay, A ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Folic acid; Homocysteine; Hormone therapy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; FOLIC ACID; HOMOCYSTEINE; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN BLOOD LEVEL; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FOLIC ACID BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; LIPID ANALYSIS; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; CONTRACEPTIVE AGENTS, FEMALE; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FLUORESCENCE POLARIZATION; FOLIC ACID; HEMATINICS; HOMOCYSTEINE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; VITAMIN B 12;

EID: 24044465519     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130500191040     Document Type: Article

References (27)

1. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281:1817-21
2. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1-7
3. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease. A critical review of the evidence. JAMA 2003;290:932-40
4. Selhub J, Jacques PF, Wilson PWF, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8
5. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 1998;316:894-8
6. Lobo A, Naso A, Arheart K, et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol 1999;83:821-5
7. Morris M, Jacques P, Selhub J, et al. Total homocysteine and estrogen status indicators in the Third National Health and Nutritional Examination Survey. Am J Epidemiol 2000; 152:140-8
8. Wouters MG, Moorees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;11:801-5
9. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000;85: 214
10. Ventura P, Cagnacci A, Malmusi S, et al. Continuous combined hormone replacement therapy with oral 17β-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women. Menopause 2001; 8:252-8
11. Somekawa Y, Kobayashi K, Tomura S, et al. Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal women. Fertil Steril 2002;77:481-6
12. Christodoulakos G, Lambrinoudaki I, Panoulis C, et al. Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women. Fertil Steril 2003;79:455-6
13. Chiantera V, Sarti CD, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003;10:286-91
14. Kaleli B, Yildirim B, Demir S, et al. Effects of low-dose 17β-estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women. Acta Obstet Gynecol Scand 2003;82:1107-11
15. Christodoulakos GE, Panoulis CPC, Lambrinoudaki IV, et al. Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmonopausal women. Eur J Obstet Gynecol Reprod Biol 2004;112:74-9
16. Cagnacci A, Malmusi S, Zanni AL, et al. Comparison of the effect of oral and transdermal hormone therapy on fasting and postmethionine homocysteine levels. Fertil Steril 2004;81: 99-103
17. Lacut K, Oger E, Abalain JH, et al. Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomized placebo-controlled trial. Atherosclerosis 2004;174: 173-80
18. Berger PB, Herrmann RR, Dumesic DA. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo Clin Proc 2000;75:18-23
19. Ghezzi F, Buttarelli M, Cromi A, et al. Plasma homocysteine levels after hormone therapy with and without folic acid supplementation: a randomized study. Fertil Steril 2004;82:746-8
20. Evio S, Tiitinen A, Turpeinen U, et al. Failure of combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 2000;74:1081-3
21. Smolders RGV, van der Mooren MJ, Teerlink T, et al. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels. Fertil Steril 2003;79:261-7
22. Marchesoni D, Driul L, Plaino L, et al. Menopause rather than estrogen modifies plasma homocysteine levels. Int J Gynaecol Obstet 2003;81:293-7
23. Mijatovic V, Netelenbos C, van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-9
24. Haas JS, Kaplan CP, Gerstenberger EP, et al. Changes in the use of hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-8
25. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
26. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-33
27. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002;137:834-9